Haemonetics Corporation Announces CEO Presentation at 44th Annual J.P. Morgan Healthcare Conference
Haemonetics Corporation (NYSE: HAE), a Boston‑based global medical‑technology company that designs, manufactures, and markets automated blood‑processing systems, has confirmed that its President and Chief Executive Officer, Chris Simon, will deliver a presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. Pacific Time.
The conference, a premier event for healthcare executives and investors, offers Haemonetics a high‑profile platform to discuss strategic initiatives, market performance, and future growth prospects. The presentation will be streamed live via an audio webcast, which can be accessed at the following URL:
Investors and analysts may also view the event on Haemonetics’ Investor Relations website. A replay of the session will be made available for 30 days following the live broadcast, starting approximately one hour after the presentation concludes.
Company Overview
Haemonetics specializes in automated blood‑processing systems tailored for:
- Surgical blood salvage
- Blood component collections
- Plasma collections
These solutions are deployed worldwide, supporting hospitals, blood banks, and plasma centers in optimizing operations and improving patient outcomes. The company’s products are positioned to address critical medical needs, offering end‑to‑end plasma collection technologies and tools that enable blood centers to collect in‑demand blood components efficiently.
Key corporate facts include:
| Metric | Value |
|---|---|
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Exchange | New York Stock Exchange |
| Currency | USD |
| Market Capitalization | $3.85 billion |
| Price‑to‑Earnings Ratio | 23.38 |
| Close Price (2026‑01‑01) | $79.98 |
| 52‑Week High (2025‑12‑09) | $87.32 |
| 52‑Week Low (2025‑09‑25) | $47.32 |
| IPO Date | May 9, 1991 |
| Website | www.haemonetics.com |
Strategic Context
The presentation will likely cover several pivotal themes:
- Business Performance – Highlighting recent revenue trends, gross‑margin dynamics, and geographic expansion.
- Innovation Pipeline – Detailing new product developments, regulatory milestones, and competitive differentiation.
- Operational Efficiency – Discussing manufacturing scalability, supply‑chain resilience, and cost‑control initiatives.
- Market Outlook – Providing guidance on market demand, reimbursement landscapes, and strategic partnerships.
While the announcement does not disclose specific content, the timing aligns with the company’s broader objective to reinforce investor confidence and showcase its commitment to delivering value through technological leadership in the blood‑processing arena.
Market Reception
The disclosure was issued via a press release on January 2, 2026 and is expected to generate interest among equity analysts covering the health‑care equipment sector, as well as institutional investors monitoring capital‑intensive medical‑technology firms. The company’s stock has traded within a $47.32 – $87.32 range over the past year, with a market cap of approximately $3.85 billion and a P/E ratio of 23.38.
Additional Company Activities
While the CEO’s conference appearance is the headline activity, Haemonetics’ broader corporate profile underscores its role as a key provider of critical infrastructure for blood banks and plasma centers. The company’s commitment to advancing standards of care is reflected in its focus on product innovation and global market reach.
This article synthesizes information from a January 2026 press release issued by Haemonetics Corporation and the company’s publicly disclosed financial and operational fundamentals.
